Pub. Date : 2012 May
PMID : 22343387
4 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | SUMMARY: Recently, vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor (VEGFR) 2 and VEGFR 3, RET, and epidermal growth factor receptor (EGFR), was approved for the treatment of adults with symptomatic or progressive MTC. | vandetanib | kinase insert domain receptor | Homo sapiens |
| 2 | SUMMARY: Recently, vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor (VEGFR) 2 and VEGFR 3, RET, and epidermal growth factor receptor (EGFR), was approved for the treatment of adults with symptomatic or progressive MTC. | vandetanib | kinase insert domain receptor | Homo sapiens |
| 3 | SUMMARY: Recently, vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor (VEGFR) 2 and VEGFR 3, RET, and epidermal growth factor receptor (EGFR), was approved for the treatment of adults with symptomatic or progressive MTC. | vandetanib | kinase insert domain receptor | Homo sapiens |
| 4 | SUMMARY: Recently, vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor (VEGFR) 2 and VEGFR 3, RET, and epidermal growth factor receptor (EGFR), was approved for the treatment of adults with symptomatic or progressive MTC. | vandetanib | kinase insert domain receptor | Homo sapiens |